Clinical Trials Directory

Trials / Completed

CompletedNCT00953693

Patient Specific Induced Pluripotency Stem Cells (PSiPS)

Status
Completed
Phase
Study type
Observational
Enrollment
15 (estimated)
Sponsor
Royan Institute · Other Government
Sex
All
Age
12 Years – 80 Years
Healthy volunteers
Accepted

Summary

Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. The reprogramming of adult cells into embryonic stem (ES) cells enables the generation of patient-specific stem cells and thus has enormous potential for the treatment and analysis of degenerative diseases. In this project the investigators are going to induce pluripotent stem cells from cell cultures from skin biopsies of patients. The iPS cells will be developed for modeling diseases and drug discovery as well as basic research.

Detailed description

iPS cells are typically derived by transfection of certain stem cell-associated genes into non-pluripotent cells, such as adult fibroblasts. Transfection is typically achieved through viral vectors, such as retroviruses. Transfected genes include the master transcriptional regulators Oct-3/4 (Pouf51) and Sox2, although to enhance the efficiency of induction some other genes e.g. Klf4, c-Myc. In this study after separation the fibroblasts from patient's skin biopsy, the cells are transfected with 4 Yamanaka factors (human Oct4, Sox2, Klf4, c-Myc) after 3-4 weeks, transfected cells are isolated through morphological selection.

Conditions

Interventions

TypeNameDescription
PROCEDUREBiopsySkin biopsy

Timeline

Start date
2009-04-01
Primary completion
2010-01-01
Completion
2010-07-01
First posted
2009-08-06
Last updated
2012-12-27

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT00953693. Inclusion in this directory is not an endorsement.